Wegovy Side Effects: What to Know About Anxiety and Mood

You've noticed something feels off, and you're wondering if Wegovy is the cause

A few weeks into treatment, some people find their mood has shifted in a way they didn't expect. The nausea was on the leaflet. Fatigue, too. But a persistent low-level unease, or moments of anxiety that feel new? That's harder to place, and it can make you question whether the medicine is the right choice for you.

It's a reasonable question to ask. Wegovy (semaglutide) acts on GLP-1 receptors found not only in the gut but also in the brain, which means it does have a degree of central nervous system activity. Researchers are still working out exactly what that means for mood. The short answer, based on current data, is that the picture is more complex than either "it causes anxiety" or "it definitely doesn't."

The NHS patient information for semaglutide lists mood changes as something to watch for, particularly thoughts of self-harm or suicide, which should prompt immediate medical contact. General anxiety as a standalone symptom is not catalogued as a common side effect (common being defined as affecting more than one in a hundred people) but that doesn't mean individual experiences are dismissed or irrelevant.

One misconception that floats around online is that Wegovy is known to cause anxiety in most people. That's not what the clinical data shows. But less common doesn't mean impossible, and your experience of physical symptoms such as vomiting is worth understanding too, since gut-related side effects are among the more commonly reported reactions and are sometimes part of the wider picture people are trying to make sense of.

What regulators have looked at, and where things stand

In 2023 the European Medicines Agency and the MHRA both opened reviews of GLP-1 receptor agonist medicines, including semaglutide, to examine reports of suicidal thoughts and self-harm. This followed a small number of spontaneous adverse event reports from patients and healthcare professionals.

The outcome of that review, completed in 2024, was that the available evidence did not establish a causal relationship between GLP-1 medicines and suicidal ideation. Regulators noted that obesity itself is associated with higher rates of depression and anxiety, which complicates interpretation of individual case reports. Nevertheless, monitoring continues, and prescribers are advised to discuss mental health history before initiating treatment.

For a broader picture of how semaglutide's safety profile is understood in the UK, the NHS England guidance on weight management injections addresses psychological considerations alongside the physical ones. If you're considering treatment or have questions about your current prescription, our FAQs page covers common concerns our prescribers hear.

What this means in practice: anxiety or mood changes while on Wegovy are not automatically the medicine's fault, and they are not automatically unrelated to it. The clinically sensible response is to tell your prescriber, not to guess.

When to get medical help, and what counts as urgent

Most mood changes that people attribute to semaglutide are mild and settle as the body adjusts, particularly around dose increases. But some symptoms need prompt attention rather than watchful waiting.

Contact your GP or prescriber the same day (or use 111 outside working hours) if you experience any of the following while taking Wegovy: thoughts of harming yourself or ending your life, a significant and sudden shift in mood or behaviour that those around you have noticed, panic attacks that are new or worsening, or feeling deeply detached from everyday life in a way that feels out of character.

For physical symptoms that sometimes accompany anxiety-type episodes, including severe stomach pain spreading to your back, get medical help urgently, this is a symptom of pancreatitis, an infrequent but serious side effect the MHRA highlighted in a January 2026 Drug Safety Update for GLP-1 medicines. The two things can be confused in the moment.

If you'd like to explore mood and mental health considerations alongside your weight management options, our page on Wegovy and depression and anxiety goes into more depth. For questions specific to whether semaglutide might be contributing to what you're experiencing, this page addresses the causal question directly.

Report any suspected side effects (physical or psychological) to the MHRA using the Yellow Card scheme. These reports are read. They shape future safety guidance.

Starting or continuing treatment: how semaglutide's safety is reviewed at nume

Before a prescriber at nume approves Wegovy for anyone, they review the full clinical picture, not just weight and BMI, but medical history, current medicines, and relevant background including mental health. That review happens with a real GPhC-registered Independent Prescriber reading your answers, not an automated system making the call.

If you're already on treatment elsewhere and want to move your prescription, or if you're weighing up whether Wegovy is right for you given a history of anxiety, a consultation is the place to work through that. Our clinical team regularly discusses exactly these questions with patients who arrive with understandable uncertainty.

For anyone starting from scratch, our overview of Wegovy in the UK covers the full picture of how the medicine works and what treatment involves. A broader look at Wegovy's side effect profile sets anxiety in context alongside the GI effects most people encounter first. And if safety of GLP-1 medicines is the wider question on your mind, our page on semaglutide safety addresses that directly.

Wegovy is a prescription-only medicine. A prescriber decides suitability, with your history and circumstances in full view. If you'd like that conversation, start your free consultation and our team will review your case the same day.